Clinical Trials Directory

Trials / Completed

CompletedNCT00467753

Oxcarbazepine Versus Placebo in Childhood Autism

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
5 (actual)
Sponsor
University of Medicine and Dentistry of New Jersey · Academic / Other
Sex
All
Age
5 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism.

Detailed description

The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism. Subjects will receive a psychiatric and medical evaluation by the study psychiatrist to see if she/he has any psychiatric or medical illnesses that would interfere with their ability to participate in this study. These evaluations may take up to an hour to complete. In addition, subjects will be asked to participate in a psychiatric interview designed to determine the child's diagnosis and current problem areas. The subject's parent will also be asked to fill out psychiatric questionnaires. The interview and questionnaires may take up to 4 hours to complete.

Conditions

Interventions

TypeNameDescription
DRUGOxcarbazepineOxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
OTHERPlacebo/sugar pillDosage similar to active drug

Timeline

Start date
2006-04-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2007-05-01
Last updated
2021-01-13
Results posted
2013-12-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00467753. Inclusion in this directory is not an endorsement.